Ms. Chunias has extensive experience representing corporations and individuals in connection with civil and criminal government investigations and prosecutions, most notably in relation to alleged violations of the Foreign Corrupt Practices Act and the federal False Claims Act, as well as health care fraud, securities fraud, insider trading, visa fraud, and export violations.
Ms. Chunias also has extensive experience conducting internal investigations for public companies, audit committees, and other special board committees, including investigations into whistleblower complaints arising under the Sarbanes-Oxley Act and Dodd-Frank Act.
In the FCPA context, Ms. Chunias has handled investigations for clients with operations in China, Hong Kong, Thailand, Mexico, Russia, the Ukraine and Germany. She routinely works with clients on the development and implementation of appropriate policies and remedial actions to address compliance and internal control deficiencies identified through such investigations, and advises technology, private equity, and other clients on FCPA and other global corruption risks in IPO and transactional due diligence contexts.
Among her recent matters, Ms. Chunias has represented:
- A global technology company in connection with False Claim Act qui tam litigation and criminal investigations by the U.S. Attorney's Office and the U.S. Department of Justice, National Security Division, relating to defense contracts and allegations of visa fraud, contract fraud, and ITAR violations.
- The Audit Committee of a public software company in connection with whistleblower allegations of FCPA violations in the Company’s Hong Kong office;
- The Special Board Committee of a public medical technology company in relation to an internal investigation of whistleblower allegations of FCPA violations and bribery relating to import of company products into Russia and Eastern Europe;
- A U.S.-based global manufacturer of scientific instruments and medical devices in connection with investigations by the SEC, DOJ and Hong Kong Independent Commission Against Corruption into alleged bribery and corruption violations at several of the Company's China subsidiaries, including relating to the use of third-party intermediaries in connection with contracts with state-owned entities;
- A financial consulting firm in False Claim Act and class action litigation arising out of “pay-to-play” allegations relating to the New Mexico State pension system;
- The former CEO of a pharmaceutical and medical device company in connection with a federal indictment relating to the company's sale of allegedly unapproved and adulterated drugs, successfully arguing for a significant downward departure following the entry of a guilty plea;
- A private healthcare consulting firm in connection with multiple FCA qui tam whistleblower suits arising out of allegations that the company assisted hospitals seeking and receiving inflated Medicare and Medicaid reimbursements;
- A national pension consulting firm in connection with claims relating to the Madoff Ponzi scheme; and
- The former president of a publicly-traded home healthcare company in connection with an investigation by the DOJ, successfully arguing for a significant downward departure following entry of a guilty plea on charges of money laundering and filing false tax returns.